Insider Buying: Gain Therapeutics, Inc. (NASDAQ:GANX) Director Buys $20,740.00 in Stock

Gain Therapeutics, Inc. (NASDAQ:GANX) Director Eric I. Richman bought 17,000 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was acquired at an average price of $1.22 per share, for a total transaction of $20,740.00. Following the completion of the transaction, the director now owns 289,629 shares in the company, valued at $353,347.38. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gain Therapeutics Stock Down 2.9 %

Shares of NASDAQ GANX opened at $1.16 on Thursday. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average price of $2.19 and a two-hundred day moving average price of $3.26. Gain Therapeutics, Inc. has a 1 year low of $1.11 and a 1 year high of $5.33.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. As a group, equities analysts forecast that Gain Therapeutics, Inc. will post -1.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on GANX shares. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target on shares of Gain Therapeutics in a research note on Tuesday, April 23rd. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a research note on Wednesday, March 27th. Finally, HC Wainwright decreased their price target on Gain Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.